Jin Hyun Nam
Overview
Explore the profile of Jin Hyun Nam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim H, Seo J, Nam J, Lim Y, Choi K, Kim K
Front Pharmacol
. 2024 Nov;
15:1443175.
PMID: 39545068
Objectives: This study compared the ischemic cardiovascular events (iCVEs) effectiveness and safety of initiating empagliflozin or dapagliflozin with those of dipeptidyl peptidase-4 inhibitors (DPP-4is), as well as the comparative effects...
2.
Lee J, Nam J, Kwon S, Kim B, Ha S
Cancer Med
. 2024 Jul;
13(14):e70030.
PMID: 39030811
Purpose: There is a lack of real-world data in Asian populations for brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non-small cell lung cancer (NSCLC). This study...
3.
Chae Y, Kwon S, Nam J, Kang E, Im J, Kim H, et al.
Expert Rev Clin Pharmacol
. 2024 Jun;
17(8):721-729.
PMID: 38832475
Objective: This study was conducted to investigate the effects of glucagon-like peptide-1 receptor (GLP-1) agonists on the lipid profiles of patients with type 2 diabetes. Methods: We retrieved the data...
4.
Jung H, Kwon S, Nam J, Cho J, Lee E
Curr Med Res Opin
. 2024 May;
:1-9.
PMID: 38715458
Objective: We assessed the real-world effectiveness of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors as first-line treatments in postmenopausal patients with HR+/HER2- advanced breast cancer, focusing on younger (<45 years)...
5.
Min S, Kwon S, Lee E, Nam J
J Infect Public Health
. 2024 Jan;
17(3):478-485.
PMID: 38271751
Background: Poor adherence to tuberculosis (TB) treatment is an obstacle to controlling the disease. The Korean government's national TB control plan includes a program on adherence to TB treatment to...
6.
Deng Q, Gupta A, Jeon H, Nam J, Yilmaz A, Chang W, et al.
Front Genet
. 2023 Jul;
14:1079198.
PMID: 37501720
Genome-wide association studies (GWAS) have successfully identified a large number of genetic variants associated with traits and diseases. However, it still remains challenging to fully understand the functional mechanisms underlying...
7.
Lee J, Kwon S, Kwon S, Jung H, Nam J, Lee E
JAMA Netw Open
. 2023 Jul;
6(7):e2324852.
PMID: 37477917
Importance: Proton pump inhibitors (PPIs) are commonly used drugs to relieve gastrointestinal tract symptoms, but their acid-inhibitory action negatively affects the bioavailability and clinical outcomes of orally administered concomitant drugs....
8.
Park H, Kwon J, Kim H, Kwon S, Nam J, Min S, et al.
J Korean Med Sci
. 2023 Jun;
38(21):e167.
PMID: 37270920
Background: Regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB) have been changed from injectable-containing regimens to all-oral regimens. The economic effectiveness of new all-oral regimens compared with conventional injectable-containing regimens...
9.
Oh B, Cho A, Nam J, Yang S, Kim M, Kwon S, et al.
BMC Cancer
. 2023 May;
23(1):482.
PMID: 37248452
Background: We aimed to examine whether patients with de novo and relapsed/progressed stage IIIB-IV non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)...
10.
Oh B, Lee J, Nam J, Hong J, Kwon S, Lee E
Front Pharmacol
. 2022 Dec;
13:908837.
PMID: 36479200
The utility values are increasingly being used in economic evaluations and health policy decision making. This study aims to conduct a systematic literature review and meta-analysis of the utility values...